COVID-19 and chronological aging: senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection?
Identifieur interne : 002680 ( Ncbi/Merge ); précédent : 002679; suivant : 002681COVID-19 and chronological aging: senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection?
Auteurs : Camillo Sargiacomo [Royaume-Uni] ; Federica Sotgia [Royaume-Uni] ; Michael P. Lisanti [Royaume-Uni]Source :
- Aging [ 1945-4589 ] ; 2020.
Abstract
COVID-19, also known as SARS-CoV-2, is a new emerging zoonotic corona virus of the SARS (Severe Acute Respiratory Syndrome) and the MERS (Middle East Respiratory Syndrome) family. COVID-19 originated in China and spread world-wide, resulting in the pandemic of 2020. For some reason, COVID-19 shows a considerably higher mortality rate in patients with advanced chronological age. This begs the question as to whether there is a functional association between COVID-19 infection and the process of chronological aging. Two host receptors have been proposed for COVID-19. One is CD26 and the other is ACE-2 (angiotensin-converting enzyme 2). Interestingly, both CD26 and the angiotensin system show associations with senescence. Similarly, two proposed therapeutics for the treatment of COVID-19 infection are Azithromycin and Quercetin, both drugs with significant senolytic activity. Also, Chloroquine-related compounds inhibit the induction of the well-known senescence marker, Beta-galactosidase. Other anti-aging drugs should also be considered, such as Rapamycin and Doxycycline, as they behave as inhibitors of protein synthesis, blocking both SASP and viral replication. Therefore, we wish to speculate that the fight against COVID-19 disease should involve testing the hypothesis that senolytics and other anti-aging drugs may have a prominent role in preventing the transmission of the virus, as well as aid in its treatment. Thus, we propose that new clinical trials may be warranted, as several senolytic and anti-aging therapeutics are existing FDA-approved drugs, with excellent safety profiles, and would be readily available for drug repurposing efforts. As Azithromycin and Doxycycline are both commonly used antibiotics that inhibit viral replication and IL-6 production, we may want to consider this general class of antibiotics that functionally inhibits cellular protein synthesis as a side-effect, for the treatment and prevention of COVID-19 disease.
DOI: 10.18632/aging.103001
PubMed: 32229706
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000109
- to stream PubMed, to step Curation: 000109
- to stream PubMed, to step Checkpoint: 000287
Links to Exploration step
pubmed:32229706Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">COVID-19 and chronological aging: senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection?</title><author><name sortKey="Sargiacomo, Camillo" sort="Sargiacomo, Camillo" uniqKey="Sargiacomo C" first="Camillo" last="Sargiacomo">Camillo Sargiacomo</name><affiliation wicri:level="4"><nlm:affiliation>Translational Medicine, School of Science, Engineering and Environment (SEE), University of Salford, Greater Manchester, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Translational Medicine, School of Science, Engineering and Environment (SEE), University of Salford, Greater Manchester</wicri:regionArea><orgName type="university">Université de Salford</orgName><placeName><settlement type="city">Manchester</settlement><settlement type="town">Salford</settlement><region type="nation">Angleterre</region><region nuts="2" type="region">Grand Manchester</region></placeName></affiliation></author><author><name sortKey="Sotgia, Federica" sort="Sotgia, Federica" uniqKey="Sotgia F" first="Federica" last="Sotgia">Federica Sotgia</name><affiliation wicri:level="4"><nlm:affiliation>Translational Medicine, School of Science, Engineering and Environment (SEE), University of Salford, Greater Manchester, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Translational Medicine, School of Science, Engineering and Environment (SEE), University of Salford, Greater Manchester</wicri:regionArea><orgName type="university">Université de Salford</orgName><placeName><settlement type="city">Manchester</settlement><settlement type="town">Salford</settlement><region type="nation">Angleterre</region><region nuts="2" type="region">Grand Manchester</region></placeName></affiliation></author><author><name sortKey="Lisanti, Michael P" sort="Lisanti, Michael P" uniqKey="Lisanti M" first="Michael P" last="Lisanti">Michael P. Lisanti</name><affiliation wicri:level="4"><nlm:affiliation>Translational Medicine, School of Science, Engineering and Environment (SEE), University of Salford, Greater Manchester, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Translational Medicine, School of Science, Engineering and Environment (SEE), University of Salford, Greater Manchester</wicri:regionArea><orgName type="university">Université de Salford</orgName><placeName><settlement type="city">Manchester</settlement><settlement type="town">Salford</settlement><region type="nation">Angleterre</region><region nuts="2" type="region">Grand Manchester</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32229706</idno><idno type="pmid">32229706</idno><idno type="doi">10.18632/aging.103001</idno><idno type="wicri:Area/PubMed/Corpus">000109</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000109</idno><idno type="wicri:Area/PubMed/Curation">000109</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000109</idno><idno type="wicri:Area/PubMed/Checkpoint">000287</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000287</idno><idno type="wicri:Area/Ncbi/Merge">002680</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">COVID-19 and chronological aging: senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection?</title><author><name sortKey="Sargiacomo, Camillo" sort="Sargiacomo, Camillo" uniqKey="Sargiacomo C" first="Camillo" last="Sargiacomo">Camillo Sargiacomo</name><affiliation wicri:level="4"><nlm:affiliation>Translational Medicine, School of Science, Engineering and Environment (SEE), University of Salford, Greater Manchester, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Translational Medicine, School of Science, Engineering and Environment (SEE), University of Salford, Greater Manchester</wicri:regionArea><orgName type="university">Université de Salford</orgName><placeName><settlement type="city">Manchester</settlement><settlement type="town">Salford</settlement><region type="nation">Angleterre</region><region nuts="2" type="region">Grand Manchester</region></placeName></affiliation></author><author><name sortKey="Sotgia, Federica" sort="Sotgia, Federica" uniqKey="Sotgia F" first="Federica" last="Sotgia">Federica Sotgia</name><affiliation wicri:level="4"><nlm:affiliation>Translational Medicine, School of Science, Engineering and Environment (SEE), University of Salford, Greater Manchester, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Translational Medicine, School of Science, Engineering and Environment (SEE), University of Salford, Greater Manchester</wicri:regionArea><orgName type="university">Université de Salford</orgName><placeName><settlement type="city">Manchester</settlement><settlement type="town">Salford</settlement><region type="nation">Angleterre</region><region nuts="2" type="region">Grand Manchester</region></placeName></affiliation></author><author><name sortKey="Lisanti, Michael P" sort="Lisanti, Michael P" uniqKey="Lisanti M" first="Michael P" last="Lisanti">Michael P. Lisanti</name><affiliation wicri:level="4"><nlm:affiliation>Translational Medicine, School of Science, Engineering and Environment (SEE), University of Salford, Greater Manchester, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Translational Medicine, School of Science, Engineering and Environment (SEE), University of Salford, Greater Manchester</wicri:regionArea><orgName type="university">Université de Salford</orgName><placeName><settlement type="city">Manchester</settlement><settlement type="town">Salford</settlement><region type="nation">Angleterre</region><region nuts="2" type="region">Grand Manchester</region></placeName></affiliation></author></analytic><series><title level="j">Aging</title><idno type="eISSN">1945-4589</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">COVID-19, also known as SARS-CoV-2, is a new emerging zoonotic corona virus of the SARS (Severe Acute Respiratory Syndrome) and the MERS (Middle East Respiratory Syndrome) family. COVID-19 originated in China and spread world-wide, resulting in the pandemic of 2020. For some reason, COVID-19 shows a considerably higher mortality rate in patients with advanced chronological age. This begs the question as to whether there is a functional association between COVID-19 infection and the process of chronological aging. Two host receptors have been proposed for COVID-19. One is CD26 and the other is ACE-2 (angiotensin-converting enzyme 2). Interestingly, both CD26 and the angiotensin system show associations with senescence. Similarly, two proposed therapeutics for the treatment of COVID-19 infection are Azithromycin and Quercetin, both drugs with significant senolytic activity. Also, Chloroquine-related compounds inhibit the induction of the well-known senescence marker, Beta-galactosidase. Other anti-aging drugs should also be considered, such as Rapamycin and Doxycycline, as they behave as inhibitors of protein synthesis, blocking both SASP and viral replication. Therefore, we wish to speculate that the fight against COVID-19 disease should involve testing the hypothesis that senolytics and other anti-aging drugs may have a prominent role in preventing the transmission of the virus, as well as aid in its treatment. Thus, we propose that new clinical trials may be warranted, as several senolytic and anti-aging therapeutics are existing FDA-approved drugs, with excellent safety profiles, and would be readily available for drug repurposing efforts. As Azithromycin and Doxycycline are both commonly used antibiotics that inhibit viral replication and IL-6 production, we may want to consider this general class of antibiotics that functionally inhibits cellular protein synthesis as a side-effect, for the treatment and prevention of COVID-19 disease.</div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">32229706</PMID><DateRevised><Year>2020</Year><Month>04</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1945-4589</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2020</Year><Month>Mar</Month><Day>30</Day></PubDate></JournalIssue><Title>Aging</Title><ISOAbbreviation>Aging (Albany NY)</ISOAbbreviation></Journal><ArticleTitle>COVID-19 and chronological aging: senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection?</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.18632/aging.103001</ELocationID><Abstract><AbstractText>COVID-19, also known as SARS-CoV-2, is a new emerging zoonotic corona virus of the SARS (Severe Acute Respiratory Syndrome) and the MERS (Middle East Respiratory Syndrome) family. COVID-19 originated in China and spread world-wide, resulting in the pandemic of 2020. For some reason, COVID-19 shows a considerably higher mortality rate in patients with advanced chronological age. This begs the question as to whether there is a functional association between COVID-19 infection and the process of chronological aging. Two host receptors have been proposed for COVID-19. One is CD26 and the other is ACE-2 (angiotensin-converting enzyme 2). Interestingly, both CD26 and the angiotensin system show associations with senescence. Similarly, two proposed therapeutics for the treatment of COVID-19 infection are Azithromycin and Quercetin, both drugs with significant senolytic activity. Also, Chloroquine-related compounds inhibit the induction of the well-known senescence marker, Beta-galactosidase. Other anti-aging drugs should also be considered, such as Rapamycin and Doxycycline, as they behave as inhibitors of protein synthesis, blocking both SASP and viral replication. Therefore, we wish to speculate that the fight against COVID-19 disease should involve testing the hypothesis that senolytics and other anti-aging drugs may have a prominent role in preventing the transmission of the virus, as well as aid in its treatment. Thus, we propose that new clinical trials may be warranted, as several senolytic and anti-aging therapeutics are existing FDA-approved drugs, with excellent safety profiles, and would be readily available for drug repurposing efforts. As Azithromycin and Doxycycline are both commonly used antibiotics that inhibit viral replication and IL-6 production, we may want to consider this general class of antibiotics that functionally inhibits cellular protein synthesis as a side-effect, for the treatment and prevention of COVID-19 disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sargiacomo</LastName><ForeName>Camillo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Translational Medicine, School of Science, Engineering and Environment (SEE), University of Salford, Greater Manchester, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sotgia</LastName><ForeName>Federica</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Translational Medicine, School of Science, Engineering and Environment (SEE), University of Salford, Greater Manchester, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lisanti</LastName><ForeName>Michael P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Translational Medicine, School of Science, Engineering and Environment (SEE), University of Salford, Greater Manchester, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>03</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Aging (Albany NY)</MedlineTA><NlmUniqueID>101508617</NlmUniqueID><ISSNLinking>1945-4589</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Azithromycin</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Doxycycline</Keyword><Keyword MajorTopicYN="N">Hydroxy-chloroquine</Keyword><Keyword MajorTopicYN="N">Quercetin</Keyword><Keyword MajorTopicYN="N">Rapamycin</Keyword><Keyword MajorTopicYN="N">aging</Keyword><Keyword MajorTopicYN="N">antibiotic</Keyword><Keyword MajorTopicYN="N">corona virus</Keyword><Keyword MajorTopicYN="N">drug repurposing</Keyword><Keyword MajorTopicYN="N">prevention</Keyword><Keyword MajorTopicYN="N">senescence</Keyword><Keyword MajorTopicYN="N">senolytic drug therapy</Keyword><Keyword MajorTopicYN="N">viral replication</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>03</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>03</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32229706</ArticleId><ArticleId IdType="pii">103001</ArticleId><ArticleId IdType="doi">10.18632/aging.103001</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>Grand Manchester</li></region><settlement><li>Manchester</li><li>Salford</li></settlement><orgName><li>Université de Salford</li></orgName></list><tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Sargiacomo, Camillo" sort="Sargiacomo, Camillo" uniqKey="Sargiacomo C" first="Camillo" last="Sargiacomo">Camillo Sargiacomo</name></region><name sortKey="Lisanti, Michael P" sort="Lisanti, Michael P" uniqKey="Lisanti M" first="Michael P" last="Lisanti">Michael P. Lisanti</name><name sortKey="Sotgia, Federica" sort="Sotgia, Federica" uniqKey="Sotgia F" first="Federica" last="Sotgia">Federica Sotgia</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002680 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 002680 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:32229706
|texte= COVID-19 and chronological aging: senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:32229706" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |